Grant H. Skrepnek, Ph.D., R.Ph.

Professor

Pharmacy Clinical & Admin Sci

Phone (405) 271-6878 x47105

Fax (4050 271-6430

Office CPB 214

Email grant-skrepnek@ouhsc.edu

Summary

I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.


Research

Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.



Publications & Presentations

<< 20 21 22 23
    111. Skrepnek G H, Armstrong E P, Malone D C, Ramachandran S. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care. Current medical research and opinion. 2005; 21 : 261-70

    112. Skrepnek G H, Skrepnek S V. An assessment of therapeutic regimens in the treatment of acute exacerbations in chronic obstructive pulmonary disease and asthma. The American journal of managed care. 2004; 10 : S139-52

    113. Skrepnek G H, Skrepnek S V. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. The American journal of managed care. 2004; 10 : S129-38

    114. Skrepnek G H. Accounting- versus economic-based rates of return: implications for profitability measures in the pharmaceutical industry. Clinical therapeutics. 2004; 26 : 155-74

    115. Lai L K, Armstrong E P, Salcido A L, French R, Skrepnek G H. Women's perception of bone-mineral density testing and osteoporosis education in the community pharmacy. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2003; 18 : 968-76

<< 20 21 22 23



Grants

1 2 3 4 >>
    1. [Cooperative Agreement] Oklahoma State Department of Health, A Strategic Approach to Advancing Health Equity for Priority Populations with or at Risk for Diabetes – 2023 (DP-23-0020, FAIN #NU58DP007376, CFDA #93.988 (Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems). . CDC. Start Date: 2023. End Date: 2024.

    2. [Cooperative Agreement] Oklahoma State Department of Health, Chronic Disease Prevention Program: The National Cardiovascular Health Program (DP-23-0004, FAIN #NU58DP007471, CFDA #93.426 - The National Cardiovascular Health Program, CDV/Heart. CDC. Start Date: 2023. End Date: 2024.

    3. HIV Adherence Services. Start Date: 2022. End Date: 2023.

    4. Patterns of Care, Outcomes, and Barriers to Treatment Success or Vaccination Associated with Adult Community-Acquired Pneumonia in Medicaid. Misc Non-Federal. Start Date: 2021. End Date: 2022.

    5. [Service Agreement] Opioid Use Under Oklahoma Senate Bill 848.. Non-federal. Start Date: 2020. End Date: 2020.

1 2 3 4 >>



Awards and Honors


no results

Education


no results

Administrative Assignments

                                                
     1. Role: Director. Scope: Department. Date: 2019.
                                                
     2. Role: Director. Scope: Department. Description: Interim Director & Director of Academic Research. Date: 2019.